



INTERNATIONAL COURSE
**Precision Surgical
Pathology**

MAY 23/24 2019
GRANADA / SPAIN

SeAP-IAP

[Sociedad Española de Anatomía Patológica]
[International Academy of Pathology]



European Association for Haematopathology
www.haematopathology.org



ciberonc
Centro de Investigación Biomédica en Red
Cáncer

TECHNICAL SECRETARY:

mm Eventos
www.icprecisionalsurgicalpathology.com
Phone: +34 954 097 529
Email: info@seap2019granada.es

#SEAP2019G

SCAN
TO
DISCOVER



Thursday, 23 - Session 1: Gynaecological Pathology.

Chairperson: **José Palacios**. Ramón y Cajal University Hospital. Madrid. Spain.

- Selected Aspects of HPV and non-HPV Related Cervical Adenocarcinomas. **Glenn McCluggage**. Belfast Health and Social Care Trust. Belfast. UK.
- Molecular, Pathological and Clinical Classification of Endometrial Cancer. **Jaime Prat**. Autonomous University. Barcelona. Spain.
- The spectrum of Neuroendocrine Uterine Tumours. **Esther Oliva**. Massachusetts General Hospital. Boston. USA.
- Metastatic Involvement of the Female Genital Tract. Pathologic and Molecular Implications in Diagnosis and Pathogenesis. **Xavier Matías-Guiu**. Bellvitge University Hospital. Barcelona. Spain.
- Germ cell tumours of the female genital tract. A paradigm of neoplastic stemness. **Francisco Nogales**. University of Granada. Spain.

Session 2: Molecular and Breast Pathology.

Chairperson: **José Palacios**. Ramón y Cajal University Hospital. Madrid. Spain.

- The Future of Precision Pathology: Considerations for Technology adoption and Training. **Manuel Salto-Téllez**. Queen's University. Belfast. UK.
- Why Molecular Pathology in Breast Cancer? **Fernando Schmitt**. Medical Faculty of Porto University & Ipatimup, Porto, Portugal.
- Precision Medicine: Molecular Tools Enhance the Diagnosis and Management of Breast Carcinoma. **Edi Brogi**. Memorial Sloan Kettering. Cancer Center. New York. USA.
- Metaplastic Carcinoma with Sarcomatous Transformation. Histogenesis, Morphology and Molecular Aspects. **Isabel Alvarado-Cabrero**. Mexican Oncology Hospital, IMSS. Mexico.

Session 3: Urological Pathology.

Chairperson: **Julián Sanz**. San Carlos Clinic Hospital. Madrid. Spain.

- Conflictive Issues Regarding Diagnosis and Prognosis of RCC subtypes. **Ferrán Algaba**. Fundació Puigvert. Barcelona. Spain.
- New RCC Entities. **María José Merino**. National Cancer Institute. Bethesda. USA.
- Spatial and Temporal Heterogeneity in CCRCC. **José Ignacio López**. Cruces University Hospital. Bilbao. Spain.
- Histopathological and Molecular Subtyping of Bladder Cancer for Prediction of Response to Classical and New Treatments. **Arndt Hartman**. University Hospital. Erlangen. Germany.
- Divine Comedy of Prostate Cancer. **Dan Berney**. Queen Mary University. London. UK.

Friday, 24 - Session 4: Digestive and Liver Pathology.

Chairperson: **Miriam Cuatrecasas**. Hospital Clinic. Barcelona. Spain.

- Tumor Budding in Colorectal Cancer: Update 2019. **Alessandro Lugli**. Institute of Pathology, University of Bern, Switzerland.
- Hereditary GI Cancer Syndromes. **Fátima Carneiro**. Centro Hospitalar São João/Faculdade de Medicina do Porto & Ipatimup/i3S. Porto. Portugal.
- Can we understand metastatic disease? The relevance of metastatic patterns in CRC patients. **Iris Nagtegaal**. Radboud University Medical Center. The Netherlands.
- Non-alcoholic fatty liver disease: evolving concepts and perspectives. **Dina Tiniakos**. Institute of Cellular Medicine. Newcastle upon Tyne. UK.
- Aretaieion Hospital, Athens, Greece.
- Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma. **Peter Schirmacher**. University Hospital. Heidelberg. Germany.

Session 5: Bone and Soft Tissue Pathology.

Chairperson: **Cleofé Romagosa**. Vall d'Hebron University Hospital. Barcelona. Spain.

- Diagnostic clues in Vascular tumors of Bone and Soft Tissue. **Judith Bovée**. University Hospital. Leiden University Medical Center (LUMC). The Netherlands.
- Update on GIST diagnosis: morphological variants and molecular aspects. **Eva Wardelmann**. University Hospital. Münster. Germany.
- Cutaneous Mesenchymal Tumors: What should we know? **Víctor Prieto**. MD Anderson Cancer Center. Texas. USA.
- Molecularly-defined soft tissue tumors. **Adrián Mariño**. Brigham and Women's Hospital, Harvard Medical School. Boston. USA.

Session 6: Hematopathology.

Chairperson: **Santiago Montes**. Marqués de Valdecilla University Hospital. Santander. Spain.

- Myeloproliferative neoplasms: the interplay between clinical features, morphology and molecular alterations. **Falko Fend**. University Hospital. Tuebingen. Germany.
- HHV8/KSHV-Positive LPD and the spectrum of plasmablastic and plasma cell neoplasms. **Jonh Goodlad**. Queen Elizabeth University Hospital. Glasgow. UK.
- B cell lymphoma. New molecular markers. **Santiago Montes**. Marqués de Valdecilla University Hospital. Santander. Spain.
- T cell Lymphomas and Leukemias. Genetic characterization of new entities. **Miguel Ángel Piris**. Fundación Jiménez Díaz University Hospital. Madrid. Spain.